Agile Therapeutics, Inc. Completes Formal Dispute Resolution Process With The FDA; FDA's Office Of New Drugs Suggested Co. Conduct A Wear Study To Evaluate Whether Twirla Demonstrates A Similar Adhesion Performance To Xulane